Ubs Group Ag Cassava Sciences Inc Transaction History

Ubs Group Ag

$555 Billion
Q2 2025

A detailed history of Ubs Group Ag transactions in Cassava Sciences Inc stock. As of the latest transaction made, Ubs Group Ag holds 190,085 shares of SAVA stock, worth $395,376. This represents 0.0% of its overall portfolio holdings.

Number of Shares

190,085

Previous 545,815 65.17%

Holding current value

$395,376

Previous $818,000 57.95%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$1.19 - $2.24 $423,318 - $796,835	-355,730 Reduced 65.17%	190,085 $344,000
Q1 2025 May 13, 2025	SELL	$1.5 - $3.02 $577,366 - $1.16 Million	-384,911 Reduced 41.36%	545,815 $818,000
Q4 2024 Feb 14, 2025	BUY	$2.29 - $32.18 $1.93 Million - $27.1 Million	841,853 Added 947.25%	930,726 $2.2 Million
Q3 2024 Nov 14, 2024	BUY	$9.57 - $35.08 $247,480 - $907,168	25,860 Added 41.04%	88,873 $2.62 Million
Q2 2024 Aug 13, 2024	SELL	$12.35 - $26.11 $268,155 - $566,926	-21,713 Reduced 25.63%	63,013 $778,000
Q1 2024 May 13, 2024	BUY	$18.44 - $26.41 $16,411 - $23,504	890 Added 1.06%	84,726 $1.72 Million
Q4 2023 Feb 09, 2024	BUY	$12.64 - $30.11 $709,988 - $1.69 Million	56,170 Added 203.03%	83,836 $1.89 Million
Q3 2023 Nov 09, 2023	SELL	$16.64 - $25.32 $601,236 - $914,862	-36,132 Reduced 56.64%	27,666 $460,000
Q2 2023 Aug 11, 2023	BUY	$21.59 - $27.88 $120,774 - $155,960	5,594 Added 9.61%	63,798 $1.56 Million
Q1 2023 May 12, 2023	BUY	$23.46 - $36.44 $388,403 - $603,300	16,556 Added 39.75%	58,204 $1.4 Million
Q4 2022 Feb 08, 2023	BUY	$27.82 - $44.16 $306,047 - $485,804	11,001 Added 35.9%	41,648 $1.23 Million
Q3 2022 Nov 10, 2022	BUY	$16.33 - $51.06 $419,436 - $1.31 Million	25,685 Added 517.63%	30,647 $1.28 Million
Q2 2022 Aug 10, 2022	SELL	$17.22 - $38.47 $22,782 - $50,895	-1,323 Reduced 21.05%	4,962 $140,000
Q1 2022 May 16, 2022	SELL	$32.6 - $53.05 $47,302 - $76,975	-1,451 Reduced 18.76%	6,285 $233,000
Q4 2021 Feb 14, 2022	BUY	$36.77 - $90.91 $30,335 - $75,000	825 Added 11.94%	7,736 $338,000
Q3 2021 Nov 15, 2021	BUY	$41.79 - $135.3 $118,432 - $383,440	2,834 Added 69.51%	6,911 $429,000
Q2 2021 Aug 13, 2021	SELL	$32.15 - $89.72 $18,068 - $50,422	-562 Reduced 12.11%	4,077 $348,000
Q1 2021 May 12, 2021	SELL	$7.09 - $87.95 $19,008 - $235,793	-2,681 Reduced 36.63%	4,639 $209,000
Q4 2020 Feb 11, 2021	BUY	$6.79 - $12.25 $46,708 - $84,267	6,879 Added 1559.86%	7,320 $49,000
Q3 2020 Nov 12, 2020	SELL	$2.86 - $11.51 $26,609 - $107,089	-9,304 Reduced 95.47%	441 $5,000
Q2 2020 Jul 31, 2020	SELL	$2.04 - $9.64 $592,711 - $2.8 Million	-290,545 Reduced 96.75%	9,745 $30,000
Q1 2020 May 01, 2020	BUY	$3.26 - $9.65 $970,120 - $2.87 Million	297,583 Added 10993.09%	300,290 $1.23 Million
Q4 2019 Feb 14, 2020	BUY	$1.1 - $6.12 $2,658 - $14,792	2,417 Added 833.45%	2,707 $14,000
Q3 2019 Nov 14, 2019	SELL	$1.04 - $1.45 $3,604 - $5,025	-3,466 Reduced 92.28%	290 $0
Q2 2019 Aug 14, 2019	BUY	$1.02 - $1.34 $620 - $814	608 Added 19.31%	3,756 $5,000
Q1 2019 May 14, 2019	BUY	$0.92 - $1.29 $2,896 - $4,060	3,148 New	3,148 $4,000

Others Institutions Holding SAVA

# of Institutions

131

Shares Held

14.2M

Call Options Held

962K

Put Options Held

864K

View Full List

About CASSAVA SCIENCES INC

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $83.4M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

More about SAVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account